All News

handcropped.RA_.jpg

Canakinumab First FDA-Approved Therapy for Adult-Onset Still's Disease

Jack Cush, MD

Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still's disease (AOSD), the first ever FDA approved drug for AOSD.

Canakinumab, an interleukin-1 inhibitor, was FDA approved in 2013 for use children (aged 2 years and older) with systemic juvenile idiopathic arthritis and has since been approved for use in other periodic fever disorders (e.g., FMF, CAPS, TRAPS, Hyper IgD syndrome).

Read Article
EULAR 2020 Roundup

Virtual EULAR 2020 Round Up

Jack Cush, MD

In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic sclerosis.

Read Article
List.jpg (keep)

Day 4 - Top 3 from EULAR 2020

Jack Cush, MD

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
List.jpg (keep)

Day 3 - Top 5 from EULAR 2020

Jack Cush, MD

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
lupus_0.jpg

Year of the Wolf: Lupus at EULAR2020

Kathryn H. Dao, M.D.

For a disease that has been recognized since the days of Hippocrates, we are finally making some progress towards understanding systemic lupus erythematosus (SLE) and how to tame the wolf.  Listed below are the top 5 studies and their summaries presented at the recent EULAR e-Congress confer

Read Article
vial.infusion.jpg (keep)

Serum calprotectin: a better biomarker in ANCA-associated vasculitis?

David Liew, FRACP

Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this week.

Read Article
psoriatic.PIP_.JPG

Are we doing our best treating seronegative arthritides?

Olga Petryna, MD

Every time a big scientific meeting ends I ask myself a question: how is it going to affect the way I treat my patients? This year the question pertains to management of axial spondyloarthropathies and psoriatic arthritis.

Read Article
Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly better BaSDAI, improved spinal pain& ASDAS-CRP vs PBO suggestive of good clincial efficacy. No radiographic data @RheumNow https://t.co/MeXV08hcBU
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0051 presence of Structural Enthrseal Lesions (SEL) in PSO associated w/higher risk of progression to PsA: 37.5%If SEL present vs 3.4% no SEL/no arthalgia& 15.2% no SEL/+arthralgia. Highest risk in PSO w/SEL+arthralgia at 42.8% @RheumNow https://t.co/7knYXeap7l
Olga Petryna DrPetryna ( View Tweet)
How do you approach your PsA patients with suboptimal response to MTX in moderate doses?

Olga Petryna DrPetryna ( View Tweet)

#EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
Olga Petryna DrPetryna ( View Tweet)
How does virtual EULAR make you feel? @RheumNow

Olga Petryna DrPetryna ( View Tweet)

Not missing being torn between ballroom 1 and exhibit hall 2 😃 #EULAR2020 #onlinelearning #VirtualConference @RheumNow https://t.co/rHLquYPjW5
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0015 relationship btw sUA &mortality in the US: increased mortality in M w/ low sUA but not F. could be attributed to uricosuric effect of uncontrolled hyperglycemia ( high incidence of DM)? Lower Alzheimer’s mortality in M&F w/high sUA. @RheumNow https://t.co/E4HVXASKYy
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 #op0079 ASAS-MRI group offers updated definition of the structural lesions in SI joints in AxSpA: -erosion in >=2 consecutive slices or in >=3 SIJ quadrants - fat lesions w/depth >1cm in >=1SIJ quadrant are high priority candidates @RheumNow https://t.co/EU1WWqJ4h3
Olga Petryna DrPetryna ( View Tweet)
#eular2020 #op0205 phase 1 trial of novel URAT1 inhibitor D-0120 in healthy adults: safe up to 20 mg/d after 7 days. Significant reduction of sUA peaks at 4-8h & lasts up to 24h @RheumNow

Olga Petryna DrPetryna ( View Tweet)

#EULAR2020 #op0169 US claims database analysis reveals that gout and DM make for a dangerous combination: significantly higher risk of amputations in pts with gout+DM at 0.77% as oppose to DM w/out gout 0.461% & gout w/out DM 0.162% @RheumNow

Olga Petryna DrPetryna ( View Tweet)

#EULAR2020 #op0201 nationwide cohort study: higher incidence of dementia in SLE (3.9/1000pys) vs non-SLE ( 2.73/1000pys). HR 1.43. In SLE risk of Alzheimer’s 1.4x &risk of vascular dementia 1.6x Higher than non-SLE cohort. Further studies to identify mechanism needed @RheumNow

Olga Petryna DrPetryna ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×